Boehringer buys fibro-inflammatory diseases program from Kyowa Kirin

8 January 2024

Germany’s Boehringer Ingelheim closed last week with a fourth licensing deal, this one with Japan’s Kyowa Kirin (TYO: 4151) to develop a novel, first-in-class treatment for fibro-inflammatory diseases.

The new development program is part of family-owned Boehringer’s commitment to combat fibro-inflammatory diseases by developing breakthrough therapies, building on the company’s expertise and leadership in this disease area, to improve patient outcomes.

Last Wednesday, Boehringer agreed to pay up to $2 billion for Chinese firm Ribo Life Science’s small interfering RNA (siRNA) therapies to treat metabolic dysfunction-associated steatohepatitis (MASH). The next day it revealed a deal with 3T Biosciences for T cell-based cancer immunotherapies, as well as a collaboration with Enara Bio.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK